Array Digital Infrastructure, Inc.(AD)Earnings, Financials & Key RatiosArray Digital Infrastructure, Inc. (AD) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's forward EV/EBITDA multiple of 60.65 suggests an expensive valuation relative to the operational uncertainty inherent in its new, smaller infrastructure-focused business model.
Array Digital Infrastructure, Inc. (AD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Array Digital Infrastructure, Inc. (AD) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $2.08vs $0.91+127.8% | $52Mvs $54M-4.3% |
| Q1 2026 | Feb 20, 2026 | $0.48vs $0.32+50.0% | $60Mvs $57M+6.7% |
| Q4 2025 | Nov 7, 2025 | $0.97vs $0.25+288.0% | $47Mvs $52M-8.6% |
| Q3 2025 | Aug 11, 2025 | $0.36vs $0.33+9.1% | $916Mvs $916M-0.0% |
Recent stock market news and headlines for Array Digital Infrastructure, Inc. (AD)
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positi
FORT LAUDERDALE, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- AD Mortgage , a leading wholesale lender in the United States, today released findings from its latest broker survey, Non-QM Fuels Mortgage Industry in 2026 revealing strong momentum for Non-QM lending across the mortgage industry.
NOT FOR DISTRIBUTION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW.
VANCOUVER, British Columbia, June 18, 2026 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc., a Vancouver-based biopharmaceutical company focused on skin health and longevity, today announced positive preclinical results for its novel small molecule, DB-006. The compound demonstrated high efficacy in treating atopic dermatitis (AD), significantly reducing key disease drivers, including pruritus (itch), epithelial thickening, inflammation, and immunoglobulin E (IgE) levels.
Key metrics vs top competitors for Array Digital Infrastructure, Inc. (AD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $34.88 | $3B | 10.47 | -95.68% | 178.52% | 8.1% | 65.25% | |
| $10.77 | $2.62B | 2.21 | 91.49% | 40.53% | — | — | |
| $6.44 | $6.63B | -3.68 | -5.39% | -14.34% | -79.42% | — | |
| $11.66 | $583.66M | -3.07 | -5.82% | -17.88% | — | — | |
| $61.81 | $1.77B | 15.73 | -13.8% | 45.58% | 6.41% | — | |
| $24.25 | $372.66M | -24.74 | -0.15% | -1.29% | -1.54% | — |
Array Digital Infrastructure, Inc. (AD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when AD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Array Digital Infrastructure, Inc. (AD) stock FAQ — growth, dividends, profitability & financials explained
Array Digital Infrastructure, Inc. (AD) reported $1.08B in revenue for fiscal year 2025. This represents a 72% decrease from $3.89B in 2014.
Array Digital Infrastructure, Inc. (AD) saw revenue decline by 95.7% over the past year.
Yes, Array Digital Infrastructure, Inc. (AD) is profitable, generating $450.4M in net income for fiscal year 2025 (178.5% net margin).
Yes, Array Digital Infrastructure, Inc. (AD) pays a dividend with a yield of 65.25%. This makes it attractive for income-focused investors.
Array Digital Infrastructure, Inc. (AD) has a return on equity (ROE) of 8.1%. This is below average, suggesting room for improvement.
Array Digital Infrastructure, Inc. (AD) generated $3.58B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
